Sangamo Therapeutics Stock Quote SGMO - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.885

Bid

0.87

Ask

0.883

Volume

123,708,549

0.695 Day's Range 1.14

0.2911 52 Week Range 1.48

Market Cap

183.646M

Previous Close

0.672

Open

0.7133

Last Trade

100

0.885

(formt)

Last Trade Time

Financial Volume

$ 109,140,865

VWAP

0.882242

Average Volume (3m)

7,272,048

Shares Outstanding

207,510,076

Dividend Yield

PE Ratio

-0.69

Earnings Per Share (EPS)

-1.24

Revenue

176.23M

Net Profit

-257.83M

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemoph... Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.sangamo.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Sangamo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SGMO. The last closing price for Sangamo Therapeutics was $0.67. Over the last year, Sangamo Therapeutics shares have traded in a share price range of $ 0.2911 to $ 1.48.

Sangamo Therapeutics currently has 207,510,076 shares outstanding. The market capitalization of Sangamo Therapeutics is $139.45 million. Sangamo Therapeutics has a price to earnings ratio (PE ratio) of -0.69.

Form 8-K - Current report

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.475	115.853658537	0.41	1.14	0.3723	56800030	0.57558199	CS
4	0.4779	117.391304348	0.4071	1.14	0.304	17587555	0.54538005	CS
12	0.363	69.5402298851	0.522	1.14	0.304	7272048	0.54374194	CS
26	0.4374	97.7211796247	0.4476	1.48	0.304	4562770	0.61973094	CS
52	-0.475	-34.9264705882	1.36	1.48	0.2911	3134178	0.61588973	CS
156	-8.995	-91.0425101215	9.88	11.49	0.2911	2103078	2.50737938	CS
260	-10.955	-92.5253378378	11.84	19.43	0.2911	1941952	5.35138843	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M